Ross Law

5 days ago | pharmaceutical-technology.com | Ross Law

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for purpose. According to McKinsey research, first-time starters now account for approximately 40% of new FDA-approved assets but experience lower success rates than established organisations. Image credit: PeopleImages.com – Yuri A via Shutterstock.

1 week ago | medicaldevice-network.com | Ross Law

The US Food and Drug Administration (FDA) has approved Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI). The California-based company’s iSNM system is implanted near the sacral nerve, with therapy activated using an external disc worn against the lower back for around two hours each day. Neuspera’s FDA approval was based on data from its pivotal Phase II study.

1 week ago | medicaldevice-network.com | Ross Law

Beset by seemingly endless caseloads and responsibilities, within the UK National Health Service (NHS) and other healthcare systems globally, burnout among general practitioners (GPs) is on the rise. A 2024 survey of 3,200 GP registrars (those in training to become fully-fledged GPs) by the British Medical Association (BMA) found that almost three-quarters of respondents are experiencing as a direct result of their clinical posting.

1 week ago | medicaldevice-network.com | Ross Law

Johnson & Johnson (J&J) MedTech has launched two new plating systems for distal radius (wrist) and proximal humerus fractures for its Variable Angle Optimised Locking Technology (VOLT) plating system in the US. Launched in October 2024, VOLT is a fracture management platform designed to improve the stability of fitted plates and streamline workflow efficiencies in orthopaedic surgery. The system initially included mini and small fragment plating systems.

1 week ago | medicaldevice-network.com | Ross Law

Amid reports that Exo could pull in $100m from investors, the imaging startup has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for two AI-based apps that detect two common lung conditions with its Exo Iris point-of-care ultrasound (POCUS) device. The newly cleared apps detect pleural effusion and consolidation/atelectasis – conditions caused by the buildup of fluid in the space between the lungs and chest wall and the collapse of lung tissue, respectively.